Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer (OC). To augment their activity, we used priming with the hypomethylating agent guadecitabine in a phase II study. METHODS: Eligible patients had platinum-resistant OC, normal organ function, measurable disease, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Siqi, Xie, Ping, Cowan, Matthew, Huang, Hao, Cardenas, Horacio, Keathley, Russell, Tanner, Edward J., Fleming, Gini F., Moroney, John W., Pant, Alok, Akasha, Azza M., Davuluri, Ramana V., Kocherginsky, Masha, Zhang, Bin, Matei, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282926/
https://www.ncbi.nlm.nih.gov/pubmed/35671108
http://dx.doi.org/10.1172/JCI158800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282926/
https://www.ncbi.nlm.nih.gov/pubmed/35671108
http://dx.doi.org/10.1172/JCI158800

Ejemplares similares